1. Pink Sheet
  2. >>Geography

African Regulators Reach Big WHO Milestones

 
• By Francesca Bruce

Egypt is the first African country to win a WHO maturity level 3 benchmarking rating for medicines and vaccines that are locally produced and imported.

African regulators earn higher WHO accreditations (Shutterstock)

Regulators in Africa are building momentum after authorities in Egypt, Rwanda and Senegal attained a maturity level 3 (ML3) in the World Health Organization’s formal process for global benchmarking of national regulatory bodies.

“Maturity level 3 reflects a stable, well-functioning, and integrated regulatory system,” said the WHO. However, ML4 is the highest level, and represents an advanced regulatory system committed to continuous improvement.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Middle East & Africa

African Medicines Agency Set To Launch With New Leader In April

 
• By Anabel Costa-Ferreira

The African Medicines Agency is to appoint a director general and become operational at the end of this month.

New Measures Can Cut Israel’s Drug Approval Time To Just 70 Days

 
• By Neena Brizmohun

Israel has introduced a new framework to expedite the marketing approval of medicines, make the country a more attractive destination for drug registration and help reduce drug prices through market competition.

Landmark Pilot Paves Way for Faster Drug Approvals In Africa

 
• By Anabel Costa-Ferreira

In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.

Africa Partners With PIC/S To Elevate GMP Standards And Accelerate AMA’s Rollout

 
• By Neena Brizmohun

Efforts have stepped up to enhance Africa’s capacity to meet international good manufacturing practice standards, empower regulators across the continent, and drive sustainable growth in the pharmaceutical sector.

More from Pink Sheet

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.